VIDEO: Lessons can be learned from terminated galegenimab study
Click Here to Manage Email Alerts
SEATTLE — In this Healio Video Perspective from the ASRS meeting, David A. Eichenbaum, MD, FASRS, overviews the efficacy of aHtrA1 Fab for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
According to Eichenbaum, 20 mg galegenimab did not affect the rate of growth of geographic atrophy lesions at any time point in the phase 2 GAllego study, which was terminated early due to an increased rate of intraocular inflammation in participants who received galegenimab.
“We can learn from this,” he said. “We can learn that anti-HtrA1 in this form is not effective, but we know because of that locus that there may be other opportunities for development and modulation at that point in the macular degenerative pathophysiologic cascade.”
Collapse
Eichenbaum D. Efficacy and safety of anti-high temperature requirement A1 (aHtrA1) Fab in geographic atrophy (GA) secondary to AMD: GAllego phase 2 randomized trial. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.
Click Here to Manage Email Alerts